Literature DB >> 3302111

Serum insulin-like growth factor-I levels in amyotrophic lateral sclerosis.

G D Braunstein, A L Reviczky.   

Abstract

The serum concentrations of the myotrophic hormone insulin-like growth factor-I (IGF-I) in 23 patients with amyotrophic lateral sclerosis were not significantly different from those found in the sera of 13 control patients. There was no difference in binding of 125I-IGF-I by serum from patients with amyotrophic lateral sclerosis in comparison with that found in the controls. These results indicate that immunoreactive IGF-I concentrations are normal in patients with amyotrophic lateral sclerosis and that such patients do not have significant antibodies binding their endogenous IGF-I.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3302111      PMCID: PMC1032090          DOI: 10.1136/jnnp.50.6.792

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay.

Authors:  R W Furlanetto; L E Underwood; J J Van Wyk; A J D'Ercole
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

Review 2.  Insulin and growth hormone: regulators of growth with particular reference to muscle.

Authors:  D B Cheek; J E Graystone
Journal:  Kidney Int       Date:  1978-10       Impact factor: 10.612

Review 3.  Somatomedin activity in disorders of nutrition and metabolism.

Authors:  L S Phillips; T G Unterman
Journal:  Clin Endocrinol Metab       Date:  1984-03

4.  Insulin-like growth factor I/somatomedin C (IGF-I/Sm C): comparison of natural, solid phase synthetic and recombinant DNA analog peptides in two radioligand assays.

Authors:  D Schalch; D Reismann; C Emler; R Humbel; C H Li; M Peters; E Lau
Journal:  Endocrinology       Date:  1984-12       Impact factor: 4.736

5.  Inhibition of terminal axonal sprouting by serum from patients with amyotrophic lateral sclerosis.

Authors:  M E Gurney; A C Belton; N Cashman; J P Antel
Journal:  N Engl J Med       Date:  1984-10-11       Impact factor: 91.245

Review 6.  Somatomedins (first of two parts).

Authors:  L S Phillips; R Vassilopoulou-Sellin
Journal:  N Engl J Med       Date:  1980-02-14       Impact factor: 91.245

7.  Pitfalls in the somatomedin-C radioimmunoassay.

Authors:  R W Furlanetto
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

8.  Distinct biologically active receptors for insulin, insulin-like growth factor I, and insulin-like growth factor II in cultured skeletal muscle cells.

Authors:  F Beguinot; C R Kahn; A C Moses; R J Smith
Journal:  J Biol Chem       Date:  1985-12-15       Impact factor: 5.157

9.  Stimulation and inhibition of myoblast differentiation by hormones.

Authors:  J R Florini; D Z Ewton; M J Evinger-Hodges; S L Falen; R L Lau; J F Regan; B M Vertel
Journal:  In Vitro       Date:  1984-12
  9 in total
  3 in total

Review 1.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

Review 2.  Motor neuron-immune interactions: the vicious circle of ALS.

Authors:  Ana G Barbeito; Pinar Mesci; Séverine Boillée
Journal:  J Neural Transm (Vienna)       Date:  2010-06-15       Impact factor: 3.575

Review 3.  Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.

Authors:  Stacey A Sakowski; Adam D Schuyler; Eva L Feldman
Journal:  Amyotroph Lateral Scler       Date:  2009-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.